DS
TSHA icon

David Shaw’s Taysha Gene Therapies TSHA Stock Holding History

David Shaw’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30M Sell
4,398,652
-28,649
-0.6% -$170K 0.01% 1044
2026
Q1 		$19.8M Buy
4,427,301
+413,666
+10% +$1.92M 0.01% 1151
2025
Q4 		$22.1M Buy
4,013,635
+1,307,201
+48% +$6.35M 0.01% 1190
2025
Q3 		$8.85M Buy
2,706,434
+2,304,925
+574% +$6.53M 0.01% 1787
2025
Q2 		$927K Buy
+401,509
New +$872K ﹤0.01% 3288
2022
Q4 		– Sell
-107,274
Closed -$207K – 5132
2022
Q3 		$207K Sell
107,274
-27,311
-20% -$99.1K ﹤0.01% 4465
2022
Q2 		$501K Buy
134,585
+59,851
+80% +$237K ﹤0.01% 4086
2022
Q1 		$487K Buy
+74,734
New +$559K ﹤0.01% 4383
2021
Q3 		– Sell
-11,448
Closed -$243K – 5245
2021
Q2 		$243K Buy
+11,448
New +$264K ﹤0.01% 4373

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's TSHA Position: Q2 2026 in Review

David Shaw reduced its Taysha Gene Therapies (TSHA) stake by 0.65% in Q2 2026, selling an estimated $170K and leaving 4,398,652 shares worth $30M. The position accounts for 0.01% of the portfolio, ranked #1044.

David Shaw first reported a position in TSHA in Q2 2021 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • David Shaw held 4,398,652 shares of Taysha Gene Therapies worth $30M as of Q2 2026.
  • David Shaw sold 28,649 Taysha Gene Therapies shares in Q2 2026, an estimated $170K.
  • Taysha Gene Therapies made up 0.01% of David Shaw's portfolio in Q2 2026, its #1044 holding.
  • David Shaw first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 9 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.